QENTOROS LLC

Blacksburg, VA · Founded 2022 · CIK 0002104916 · Biotech · Private

Platelet-derived biologics for equine therapeutic applications

qentoros.com →
Grants
$900K
3 awards
Sector median: 1
Raised
$605K
2 Form D · Aug 2026
2 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · A novel therapeutic for the treatment of biofilms in periprosthetic joint infections$300,000
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · A novel therapeutic for the treatment of biofilms in periprosthetic joint infections$300,000
Federal grantDepartment of Health and Human Services · Phase I · A novel therapeutic for the treatment of biofilms in periprosthetic joint infections$300,000
Private capital raisedForm D · SEC$100,000
Private capital raisedForm D · SEC$505,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1221Aegle Therapeutics Corp—$6.7M
1222Intelligent Therapeutics, Inc.—$100K
1223CHEMITOPE GLYCOPEPTIDE, LLC—$100K
1224QENTOROS LLC—$605K
1225Tetraphase Biosciences——
1226Savara Pharma——
1227NABGEN, INC.—$100K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 2 related persons
  • Jessica GilbertieDirector · Executive Officer
  • MICHAEL MILLERDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.